Iceland’s Hepatitis C Program Cuts HIV Coinfections Significantly

A nationwide program in Iceland to eliminate hepatitis C virus (HCV) has yielded a significant, unexpected benefit: a marked reduction in new HIV/HCV coinfections. The success, stemming from widespread access to direct-acting antiviral (DAA) treatments, demonstrates the potential of “Treatment as Prevention” (TraP) strategies to impact broader public health outcomes.

Iceland’s TraP HepC Program and the Cascade of Care

Initiated in 2016, Iceland’s TraP HepC program replaced older, interferon-based treatments for HCV with newer, more effective DAAs. This shift wasn’t just about improving treatment outcomes for those already infected; it was a deliberate strategy to reduce the overall incidence of HCV and, as it turns out, its co-occurrence with HIV. A retrospective study examining data from 2000 to 2020 revealed a striking trend. Before 2016, the number of people with HIV who also tested positive for HCV antibodies was steadily increasing. However, following the implementation of TraP HepC, this number plummeted by more than 85% by 2020, falling from a peak of 41 coinfections in 2016 to just 6 in 2020. The study, published in PubMed, analyzed medical records, laboratory results, and treatment outcomes for all people with HIV in Iceland.

The concept of a “cascade of care” is central to understanding this success. The cascade refers to the steps a person with a condition goes through – from diagnosis to treatment to achieving a cure. Improvements at any stage of the cascade can have a ripple effect. In Iceland, the widespread availability of DAAs dramatically improved the treatment stage, leading to higher cure rates and, fewer people remaining infectious and able to transmit the virus.

Understanding HIV/HCV Coinfection

HIV (human immunodeficiency virus) and HCV are both bloodborne viruses, meaning they are primarily spread through contact with infected blood. For individuals infected with both viruses, the consequences can be particularly severe. HCV infection can progress more rapidly in people with HIV, and HIV can accelerate liver damage caused by HCV. Coinfection also increases the risk of liver-related complications, including cirrhosis and liver cancer. The majority of coinfections in Iceland were linked to injection drug use, highlighting the importance of harm reduction strategies.

Treatment Advances: From Interferon to Direct-Acting Antivirals

The dramatic improvement in treatment outcomes is a key driver of the observed reduction in coinfections. Prior to 2016, interferon-based therapies were the standard of care for HCV. These treatments were often associated with significant side effects and had relatively low cure rates – around 45% in the Icelandic study population during the 2000-2015 period. The introduction of DAAs, however, revolutionized HCV treatment. DAAs are highly effective, with cure rates exceeding 88% in the Icelandic study, and are generally better tolerated than interferon-based regimens. As detailed in a report from the International Health Systems Update, the shift to DAAs was a deliberate component of Iceland’s national HCV elimination campaign, aligning with the goals set by the World Health Organization.

Reinfection Rates and Ongoing Challenges

Despite the remarkable success of the TraP HepC program in reducing overall HIV/HCV coinfections, the study also revealed a concerning trend: a relatively high reinfection rate among those who achieved a cure. The reinfection rate was 9.35 per 100 person-years, and all presumed reinfections were linked to injection drug use. This underscores the need for continued prevention efforts, particularly targeted at individuals who inject drugs. Easy access to DAAs is crucial not only for initial treatment but also for re-treatment of those who develop into reinfected.

What the Study Doesn’t Tell Us

It’s important to note the limitations of this study. It was conducted in a single country – Iceland – with a relatively small population. The findings may not be directly generalizable to other settings with different demographics, healthcare systems, or patterns of HCV transmission. The study also relied on retrospective data, which is subject to potential biases, and inaccuracies. The study period ended in 2020, and it will be important to monitor trends over a longer period to assess the long-term impact of the TraP HepC program. The study also doesn’t detail the specific harm reduction programs in place alongside the TraP HepC initiative, making it difficult to isolate the impact of treatment alone.

Implications for Global HCV Elimination Efforts

Iceland’s experience provides valuable lessons for other countries striving to eliminate HCV. The success of the TraP HepC program demonstrates that universal access to DAAs can be a powerful tool for reducing both HCV incidence and its associated complications. However, it also highlights the importance of addressing the underlying risk factors for HCV transmission, such as injection drug use. The nationwide program, as described in the Journal of Internal Medicine, serves as a model for other nations considering similar approaches.

The reduction in HIV/HCV coinfections is a significant co-benefit of the HCV elimination program, demonstrating the interconnectedness of public health interventions. By focusing on eliminating one virus, Iceland has inadvertently made progress in controlling another. This underscores the importance of integrated approaches to public health that address multiple health challenges simultaneously.

Next Steps: Ongoing Surveillance and Prevention

Continued monitoring of HCV and HIV trends in Iceland is essential to assess the long-term sustainability of these gains. Public health authorities will need to maintain robust surveillance systems to detect new infections and reinfections promptly. Ongoing investment in harm reduction programs, including needle exchange programs and opioid substitution therapy, is crucial to prevent the spread of HCV among people who inject drugs. Regular reviews of treatment guidelines and access policies will also be necessary to ensure that all individuals have equitable access to the latest advancements in HCV treatment.